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Abstract. – OBJECTIVE: The association of
bilateral hypertrophy of temporalis and masse-
teric muscles is a rare clinical entity. The origin
of the condition is unclear, causing cosmetic
problems, pain, and functional impairment. 
PATIENTS AND METHODS: In this paper we
analyzed 15 patients treated at the Department
of Maxillo-Facial Surgery of the University of
Naples Federico II, from 2000 to 2013, for tem-
poralis and/or masseteric muscle hypertrophy,
and in particular, a rare case of a patient with a
marked bilateral swelling of the temporalis and
masseteric region, in conjunction with a review
of the literature.
RESULTS: Fourteen patients have not any
kind of postoperatively problems. The last pa-
tient had been aware of the swelling for many
years and complained of recurrent headaches.
We adopted a new protocol fort these patients
and the patient was very pleased with the treat-
ment results, and reported a reduction in
headaches and a continuation of his well-be-
ing, in addition to greater self-confidence. The
last follow-up was performed three years after
the first treatment, and the patient showed a
complete resolution of his symptoms, and just
a small increase of the swelling.
CONCLUSIONS: The treatment of temporalis
and masseteric hypertrophy with Botulin toxin
could be an effective option compared to con-
servative treatment or surgical intervention al-
though the review of the literature shows that
this is only a temporary treatment. In fact,
surgery still remains the best option.
The treatment must be repeated every 4/6
months for 2-3 consecutive years before hav-
ing stable benefits. To overcome this problem,
an association with a bite treatment allowed us
to achieve more lasting and more stable results
over time without a recurrence of symptoms
between the treatments. Furthermore, this as-
sociation has enabled us to obtain a more rapid
reduction of the hypertrophy. 
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Introduction
The association between bilateral hypertrophy
of temporalis and masseteric muscles is a rare
clinical entity and only few cases have been re-
ported in the literature. This phenomenon was
first described by Legg in 18801 and well de-
tailed by Dencer and Franks2-3. Temporalis and
masseteric muscle hypertrophy is regarded as re-
active in nature, but may be also idiopathic. It
occurs most commonly between the ages of 20
and 40 and is not gender-specific. Mandibular
retrognathia and masticatory muscle hyperactivi-
ty have been described as possible causes3. The
origin of the condition is unclear because masti-
catory muscle hyperactivity or parafunctions and
dysfunctions in the stomatognathic system, can-
not be verified in all instances of hypertrophy.
Compensatory and stress hypertrophy has been
assumed in most cases4. Changes in the proprio-
ceptors have also been discussed5.
From the clinical and anamnestic point of
view, attention has focused on the aesthetic as-
pect of the unilateral or bilateral hypertrophy, be-
cause of the distension in the mandibular angle
region. At the same time, the symptoms have
shown to be compounded by local pain and func-
tional impairments. In the past, the treatment of
choice for correcting the hypertrophy of these
muscles in the maxillofacial region was surgical
reduction, and attention was focused not only on
the general risks associated with the operations,
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8but also on the risk of damaging the facial
nerve6,7. Therefore, medical management utiliz-
ing botulinum toxin A, has become the treatment
of choice and has been successfully used to cor-
rect temporalis and masseteric hypertrophy. 
Materials and Methods
We analyzed 15 patients treated at the Depart-
ment of Maxillo-Facial Surgery of the University
of Naples Federico II, from 2000 to 2013, for
temporalis and/or masseteric muscle hypertro-
phy, and we describe a rare case of a 29 y.o.
male patient with marked bilateral swelling of
the temporalis and masseteric region. 
Four patients had monolateral masseteric hy-
pertrophy, two patients had monolateral tempo-
ralis muscle hypertrophy, three patients showed
homolateral masseteric and temporalis muscle
hypertrophy, while five patients had bilateral
masseteric muscle hypertrophy. 
Only one patient with bilateral masseteric and
temporalis muscle hypertrophy was observed. 
Five patients were treated by surgical reduc-
tion of the muscles. Ten patients were treated by
injection of Botulin toxin type A. 
Results
Fourteen patients have not any kind of postop-
eratively problems. The last patient had been
aware of the swelling for many years and com-
plained of recurrent headaches. The muscle bulk
was more prominent when the patient clenched
his teeth. There was no evidence of bruxism. His
clinical history began when he was 19 years old
and he noticed a swelling of the right masseteric
region (Figure 1). About three years later he re-
ported a bilateral swelling of the masseteric re-
gion and at the age of 27 also a swelling of the
temporalis region bilaterally (Figure 2). 
His orthopantomogram revealed no abnormal-
ities. An electromyography detected massive
muscle activity especially during chewing. An
ultrasound examination of the masseteric and
temporal regions was performed, and it revealed
no abnormalities of the muscles. A diagnosis of
bilateral masseteric and temporalis muscle hy-
pertrophy was suggested, so no organic abnor-
mality was found. A careful analysis of the pa-
tient’s medical history revealed deep social prob-
lems of the patient in adolescence due to difficult
relationships with the female sex. In this regard,
the patient’s friends reported that when they
were in a group together with attractive girls, he
clenched his teeth and stammered. This discom-
fort lasted for a few years and probably altered
the strength of the masseter muscle of the patient
and perhaps there had been a clearing of all the
other muscles involved in chewing.
Treatment was carried out by percutaneous in-
jection of a total of 100 Units of botox, into the
temporalis and masseteric muscles bilaterally,
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Figure 1. Patient before the onset of temporal and masse-
teric hypertrophy.
Figure 2.Patient before the treatment. 
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masseteric muscle. Within this rectangle we in-
jected 30 UI for each side at three points, taking
into consideration the possible diffusion of the
toxin. The follow-up was arranged four weeks
and eight weeks postoperatively. At the later
checkup the muscle contour had returned to nor-
mal. The treatment was repeated every 6 months.
The ultrasound showed, after 2 years of treat-
ment, a reduction in muscle thickness from 215
mm to 150 mm of masseteric muscle and from
160 mm to 90 mm of temporalis muscle. The
electromyography performed after two years de-
tected a reduction of the muscular activity both at
rest and during maximum activity. 
The patient was very pleased with the treat-
ment results, and reported a reduction in
headaches and a continuation of his well-being,
in addition to greater self-confidence. 
The last follow-up was performed three years
after the first treatment (one year after the last
treatment), and the patient showed a complete
resolution of his symptoms, and just a small in-
crease of the swelling (Figure 4) Therefore, we
decided to discontinue injection therapy but just
bite therapy during the night. To date the patient
has not deemed it necessary to carry out addi-
tional checkups because by phone he reports be-
ing well.
combined with the use of a rigid upper bite for
muscle stabilization. This dose was chosen after
several attempts made with lower and increasing
doses in patients with the same type of disease
but for different causes and with poor results. Our
first patient treated with injection of Botulin toxin
received 12 UI of Botox in the masseteric muscle,
but his symptoms reappeared after 2 months. We
increased the doses of 4 UI every 4/5 months, in
order to obtain a more stable result, until a dose
of 30 UI for each muscle was injected. 
We adopted a new protocol performed on the
last patient: for the temporalis muscle, 20 UI of
toxin each side were placed relatively deep with-
in the muscle mass at several sites to take ac-
count of the anatomy of the deep temporal
nerves, which normally enter more deeply into
the muscle. Therefore, we injected the toxin su-
perficially. We marked the temporal artery on the
ultrasound, and we highlighted three points be-
tween the artery branches where the muscle
thickness is greater. For the masseteric muscle
we defined a rectangular safety injection zone
within four lines (Figure 3). We drew the first
line linking the ear lobe and the mouth corner,
the second line along the mandible angle and the
two vertical lines marked the anterior and poste-
rior margins of the masseter muscle by palpation.
This was considered the safety zone because
there are no important anatomical structures un-
der the mouth corner/ear lobe line and because it
was the area with the greatest thickness of the
Figure 3. Infiltration points. 
Figure 4.Patient after 18 months of treatment. Stable re-
sult after 2 years.
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Discussion
Masseteric and temporalis muscle hypertro-
phy is an uncommon clinical condition of un-
certain etiology. The hypertrophy can be unilat-
eral or bilateral, affecting both males and fe-
males, but has a slight male predominance.
Since 1880, when Legg1 reported the first case
of bilateral hypertrophy of the masseter and
temporal muscle in a 10 y.o. girl, to our knowl-
edge, 130 other cases of masseteric or tempo-
ralis hypertrophy have been described in the
pertinent literature. This is a rare clinical entity
and several theories have been proposed regard-
ing the etiology, and its specific cause has not
yet been well clarified. Temporalis and masse-
teric muscle hypertrophy is regarded as reactive
in nature, but may be also idiopathic. Mandibu-
lar retrognathia and masticatory muscle hyper-
activity have been described as possible causes.
The origin of the condition is unclear because
masticatory muscle hyperactivity or parafunc-
tions and dysfunctions in the stomatognathic
system cannot be verified in all instances of hy-
pertrophy. Compensatory and stress hypertro-
phy has been assumed in most cases3. Changes
in the proprioceptors have also been discussed4. 
It can be associated with facial pain and can be
prominent enough to be considered cosmetically
disfiguring. This clinical condition can be treated
by partial surgical resectioning of the masseteric
and mandibular angle, or temporalis muscle per-
formed by an intraoral or extraoral approach, or
with conservative treatment using botulinum tox-
in type A injection. In our case load, from 2000
to 2013, fifteen patients were treated. Four pa-
tients had monolateral masseteric hypertrophy,
two patients had monolateral temporalis muscle
hypertrophy, three patients showed homolateral
masseteric and temporalis muscle hypertrophy,
five patients had bilateral masseteric muscle hy-
pertrophy, and only one patient with bilateral
masseteric and temporalis muscle hypertrophy
was observed. 
Five patients were treated by surgical reduc-
tion of the muscle, ten patients were treated with
injection of Botulin toxin type A, and one with
the association of Botulinum toxin type A injec-
tions, and a bite. 
Injection of botulinum toxin type A into the
masseter muscle was first introduced by Smyth8,
Moore and Wood9 in 1994 and was considered a
less invasive procedure for cosmetic sculpting of
the lower face. Botulinum toxin type A injection
is reported to be a safe and effective treatment in
some pathologies, such as orofacial dystonies,
sialorrhea, Frey’s syndrome, and muscle hyper-
trophies10-12.
Injection of botulinum toxin type A into the
muscles is generally considered a less invasive
procedure and has been advocated for cosmetic
sculpting of the face. Botulinum toxin type A is a
powerful neurotoxin which is produced by the
anaerobic organism Clostridium botulinum and
when injected into a muscle causes interference
with the neurotransmitter mechanism, producing
selective paralysis and subsequent atrophy of the
muscle. 
The possible complications of this procedure
are external scarring, damage to the mandibular
or temporal branches of the facial nerve, change
in bite strength, speech disturbance, muscle pain,
facial asymmetry, and prominent zygoma. Per-
haps the biggest limitation of botulinum toxin
therapy is that the effects of treatment wear off
within 6 months and the original pathological
condition returns. Many cases of masseteric mus-
cle hypertrophy are described in the literature,
but, to our knowledge, only three cases with as-
sociation of masseteric and temporalis hypertro-
phy13-15, and no cases of a progressive hypertro-
phy, like in our case, have been reported. 
This case suggests that the treatment of tempo-
ral and masseteric hypertrophy with Botox could
be an effective option compared to conservative
treatment or surgical intervention, where the
muscle bulk is disfiguring. Although Botox is ex-
pensive, intramuscular injection can be per-
formed in the outpatient clinic and costs compare
favourably to surgical costs. 
The patient need not be hospitalized and can
return to normal activity immediately. Moreover
the patient far more willingly accepts this type of
treatment without pain or the presence of un-
sightly scars. Furthermore, the final result is sat-
isfactory and improves the quality of life of the
patient. The only problem is that treatment must
be repeated every 4/6 months for consecutive 2-3
years before having stable benefits. In actual fact
initially, 2-3 months after the treatment, patients,
as reported in literature, have a gradual recur-
rence of the symptoms. To overcome this prob-
lem, we used a bite in association with botox
treatment. This association allowed us to achieve
more lasting and stable results over time without
a recurrence of symptoms between treatments.
Furthermore, this association has enabled us to
obtain a more rapid reduction of the hypertrophy. 
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Conclusions
Masseter and temporalis hypertrophy is a
benign condition with variable causative fac-
tors, such as bruxism, temporomandibular dis-
orders, malocclusion and others, but has an un-
clear etiology in the majority of cases. There
are theories described in literature, and also
progressive hypertrophy caused by episodes of
anxiety in the relationship with the opposite
sex. It can be associated with facial pain and
asymmetry. The treatment of temporal and
masseteric hypertrophy with Botox could be an
effective option compared to conservative
treatment or surgical intervention, where the
muscle bulk is disfiguring. An optimal treat-
ment is carried out by percutaneous injection
of 100 UI of botox into the temporalis and
masseteric muscles bilaterally, combined with
the use of a bite for muscle stabilization. For
the temporalis muscle 20 UI of toxin each side
are adequate to solve the hypertrophy, to be
placed relatively superficially.
For the masseteric muscle 30 UI for each side
at three points into a rectangular safety injection
zone are the best solution. The follow-up is fun-
damental at four weeks and eight weeks postoper-
atively. The treatment is repeated every 6 months.
With the association of injection of Botulin
toxin type A and a rigid upper bite we can obtain
an increase of the duration of the results and a
longer stability in time.
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